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Positron emission tomographya b s t r a c t
Drug resistant epilepsy (DRE) has been associated with a high incidence of psychotic disorders. Patients
can develop psychosis after starting a new antiseizure medication, after undergoing resective surgery, or
after implantation of a vagus nerve stimulation (VNS) system. The aim of this study was to investigate the
modulation effect of VNS on psychotic episodes in DRE patients with a pre-existing history of periictal
psychotic episodes (PPE).
We retrospectively report the outcome of four patients from a single tertiary center with PPE prior to
implantation. None of the implanted patients developed de novo PPE after VNS therapy. Regarding seizure
outcome, all patients demonstrated a response to VNS with two who experienced who status epilepticus
and three patients wtih a change in semiology with after VNS implantation. PPE disappeared in all the
study patients, two of them at 6 months post-implantation and in the others after 2 and 3 years, respec-
tively. 18F-FDG-PET results showed hypermetabolism in both anterior insular and medial frontal lobes
which disappeared in the 18F -FDG-PET 4 years post-implantation.
Based on the results of this series of cases we suggest that VNS therapy may be useful to modulatet PPE
in patients with DRE, though effectiveness may be time-dependent.
 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Psychiatric disorders affect patients with epilepsy more fre-
quently than they do the general population. The reported preva-
lence of psychotic disturbances varies between 2% and 7%, with a
pooled prevalence of 5.6% [1]. The variation becomes higher when
compared to the general population (1%), especially in those with
temporal lobe epilepsy (TLE), affecting nearly 20% of patients [2].
Psychosis may be seen based upon its temporal relationship withseizures and include preictal, ictal, and postictal psychosis. We
separated them into periictal psychotic episodes (PPE) and interic-
tal psychosis (IIP) when a relationship between psychosis and sei-
zures did not exist.
For PPE we used the same definitions as those identified by
Logsdail and Toone. PIP was a defined as appearing within one
week after a seizure or cluster of seizures, lasting from at least
15 hours up to 2 months, and preceded by a lucid period (24–
72 h). Ictal psychosis was defined as psychosis appearing simulta-
neously with a prolonged seizure or status epilepticus as the clin-
ical expression confirmed by an EEG without prominent motor
symptoms [3].
Most of the old and new antiseizure drugs (ASD) as well as sur-
gical treatment have been implicated in the emergence of PPE
[4,5]. Psychotic symptoms in epileptic patients with PPE are
thought to be influenced by a disruption in a chronic inhibitory
mechanism. Immediately after a cluster of seizures, PIP patients
Fig. 1. EEG recording during a postictal psychosis Patient with visual hallucinations and feelings of being harmed by others. EEG records show a left temporal breach rhythm
due to previous craniotomy. There were occasional interictal epileptiform discharges in the recording (box).
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tion producing a disconnection of the temporal-limbic structures
and the prefrontal structures and a loss of control over the pre-
frontal structures [6]. This concept was first introduced in 1953
by Landolt with the concept of ‘forced normalization theory’ to
describe the appearance of psychotic episodes associated with
total or partial normalization of the electroencephalogram (EEG)
in patients with epilepsy [7]. In regard to this, vagus nerve stimu-
lation (VNS) therapy has also played a role [8–11]. Paradoxically, aFig. 2. EEG recording during an ictal psychosis Patient with visual hallucinations and
epileptiform activity over T7, P7, P3 (box) and (B) subclinical seizures (42 subclinical
frontotemporal area (box).
2
positive effect in the modulation of psychiatric symptoms has been
observed in VNS treated patients, and it has been approved as a
non-pharmacological adunctive treatment for depression [12].
Moreover, a recent study conducted in an animal model for
schizophrenia found VNS provided a positive effect in controlling
psychotic symptoms [13].
We aimed to study the neuro-modulatory effect of VNS on psy-
chotic episodes in drug-resistant epilepsy (DRE) patients with a
pre-existing history of PPE in a single-center retrospective analysis.heteroaggressive behaviour. EEG record during the episode shows (A) interictal
seizures in 6 hours) starting with alpha rhythm in T8 and spreading to the right
Fig. 3. 18F-FDG-PET pre- and post-VNS implantation a) 18F-FDG-PET pre-VNS shows hypometabolism in both superior parietal lobes (^), more intense in the right
(epileptogenic area) and relative hypermetabolism in the mesial frontal areas (*) and the anterior insulas ( ). b) 18F-FDG-PET post-VNS shows less intense hypometabolism in
both superior parietal lobes (^) with a normalization of the hypermetabolism in the frontal lobes (*) and insular lobes ( ). c) Z map of the 18F-FDG-PET subtraction co-
recorded with the MRI, showing the cortical areas that underwent a change of more than 2SD in metabolism; frontal areas with a decrease of metabolism (blue blob) and
right parietal areas with increase of metabolism (orange blob). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of
this article.)
M. Alemany, E. Real, Núria Custal et al. Epilepsy & Behavior Reports 15 (2021) 100434A total of 48 patients diagnosed with DRE and treated with VNS
therapy from 2006 to 2016 were identified. None of the implanted
patients developed psychosis. In the present study we included 4
patients from the series with a prior history of PPE.
Patient evaluation included a formal intermittent psychiatric
examination, prolonged video-EEG (vEEG), structural magnetic
resonance imaging (MRI) study with a standard epilepsy protocol,
and 18F-labelled fluoro-2-deoxyglucose-positron emission tomog-
raphy (18F-FDG-PET) co-registered with MRI.3
1.1. Case 1
A 40-year-old male patient was diagnosed at the age of 23 with
non-lesional bitemporal DRE. The patient experienced 8 episodes
per month of focal impaired awareness seizure (FIAS), and occa-
sionally focal to bilateral tonic-clonic seizure (FBTCS). Several ASDs
were tested without achieving seizure control, with oxcarbazepine
(OXC), clobazam (CBM) and brivaracetam (BRV) the last combina-
tion tried. Anterior temporal lobe resection of the most affected
M. Alemany, E. Real, Núria Custal et al. Epilepsy & Behavior Reports 15 (2021) 100434temporal lobe was done at the age of 34 without changes in seizure
frequency. After nine months, the patient started suffering PIP epi-
sodes at a frequency of 3 episodes per year. PIP episodes began in
the 12–24 hours after the seizure and lasted for 3–5 days. These
episodes were characterised by a state of confusion and auditory
hallucinations, requiring hospitalization in one case. No prior his-
tory of psychotic disorder was reported. During PIP episodes nor-
mal EEG background with fronto–temporal interictal epileptiform
discharges was recorded (see Fig. 1). VNS device was implanted
one year later to achieve better seizure control. After a 5-year
follow-up seizures were reduced by 62.5% in additio to a change
in semiology (focal aware seizure with distorted body perception)
and reduced seizure severity. In terms of PIP, 3 episodes in the 2nd
year was noted and no new episodes appeared after the third year
of stimulation.1.2. Case 2
A 54-year-old male patient was diagnosed at the age of 14 with
DRE secondary to a malformation of cortical development. Bitem-
poral seizures at a frequency of 6–8 episodes per month were
reported. FIAS not preceded by aura and occasionally Focal
to bilateral tonic-clonic seizures (FBTCS) were the typical seizure
types. Several ASDs (OXC, phenytoin (PHT) and lacosamide
(LCM)) were tested without achieving seizure control. At the age
of 43 the patient started suffering recurrent episodes of postictal
psychosis which started between 8 and 12 hours after a seizure,
characterised by a state of confusion with hallucinations and para-
noia. No prior history of psychotic disorder was reported. Antipsy-
chotic treatment was initiated with quetiapine (QTP) and
haloperidol (HLP); however, episodes were still present occurring
with a frequency of 2–3 times per year, requiring hospitalization
on two occasions. VNS therapy was implanted at the age of 48.
After a 6-year follow-up seizures were reduced by 42.8% with a
change in semiology (appearing only nocturnally). No further
episodes of postictal psychosis were documented one year after
VNS implantation.1.3. Case 3
A 47-year-old female patient was diagnosed at the age of 12
with DRE secondary to a parietal tumour. Initial surgery was done
in another center when the patient was 16 and the histopathology
was reported as oligodendroglioma, with complete resection. The
patient was seizure free for 3 years but then the seizures reap-
peared and became more and more frequent. No evidence of tumor
relapse was observed. She was reoperated twice, at the ages of 25Table 1
Demographics and clinical characteristics of patients with prior history of periictal psycho
P 1 P 2
Gender Male Male
Age (Yrs) 40 54
Age at epilepsy onset (Yrs) 23 14
Aetiology Unknown Malformation of cortic
development
Seizures localization Bitemporal Bitemporal
Age at psychosis onset (Yrs) 34 43




Psychiatric disorder in relation
to seizures*
Postictal Postictal
Age at VNS implantation (Yrs) 35 48
VNS** follow-up time (Yrs) 5 6
Intensity/frequency VNS* 1 mA/ on 3000 off 50 2 mA/ on 3000 off 50
* Psychotic disorder due to epilepsy, according to DSM-IV criteria (code 293.0: Diagn
4
and 31 including a left parietal topectomy and a right amygdalo-
hippocampectomy. At the age of 36 she started suffering ictal psy-
chosis during episodes characterised by delusions, anxiety,
agitation, and heteroaggressivity. These psychotic episodes
appeared simultaneously with an exacerbation of seizure cluster-
ing. No prior history of psychotic disorder was reported. She was
monitored in our center from 2012, and at that time she suffered
1–2 seizures per day and 1 episode of psychosis per month. EEG
findings during these episodes showed seizures arising in one pari-
etal or temporal lobe evolving to contralateral areas without recov-
ery between them (see Fig. 2). Antipsychotic treatment was
initiated with QTP and clozapine (CPZ), but unfortunately the epi-
sodes remained, with a frequency of 6–8 per year. In relation to
post-surgical changes, MRI showed areas of encephalomalacia-
gliosis on the right temporal-insular cortex and left parietal sple-
nium of the corpus callosum. At the age of 43, a VNS was implanted
achieving a reduction of seizures by 82.5% and elimination of the
episodes of SE over a 4 year follow-up period. Post-VNS the semi-
ology of seizures also changed to focal aware seizures and falls.
Only 1 episode of ictal psychosis was documented in the 1st year
and was completely eliminated by the 2nd year after VNS
implantation.1.4. Case 4
A 61-year-old female patient was diagnosed at the age of 18
with non-lesional DRE, temporal and biparietal lobes. The patient
experienced FIAS not preceded by aura with a frequency of 10–
15 episodes per month, and 1–2 SE per month (starting with clus-
ters of 5–7 seizures for 3–4 hours and continuing with an altered
mental state of confusion and disorientation for 3 days). Several
ASDs were trialed without achieving seizure control. The last trial
included combination therapy with levetiracetam and lamotrigine.
At the age of 50 during periods when the frequency of seizures was
higher, the patient started suffering ictal psychosis characterised
by episodes of agitation, auditory hallucinations, and perspicuous
feelings. No prior history of psychotic disorders was reported.
Antipsychotic treatment was initiated with risperidone without
achieving control of psychotic episodes which continued with a
frequency of 2–4 per year requiring hospitalization on 7 occasions,
3 of them due to suicide attempts.
At the age of 58 VNS was implanted achieving a reduction of
seizure frequency by 60% and elimination of SE over a 4 year
follow-up period. Seizure severity also changed due to changes in
semiology to focal aware seizures with somatosensory aura in
the right foot not followed by impaired awareness most of the time
when she acutely activated magnet-induced VNS stimulation. Nosis (PPE) and VNS. therapy.
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M. Alemany, E. Real, Núria Custal et al. Epilepsy & Behavior Reports 15 (2021) 100434further psychotic episodes were documented after the first year of
VNS implantation.
Additionally, 18F-FDG-PET before VNS implantation was per-
formed showing hypometabolism in both superior parietal lobes,
more evident in the right, and relative hypermetabolism in the
mesial frontal areas and anterior insulas. 18F-FDG-PET after 4 years
following VNS implantation showed less intense hypometabolism
in both superior parietal lobes with a normalisation of the hyper-
metabolism in the frontal lobes, insular lobes, and left caudate
nucleus (shown in Fig. 3).
A summary of demographics and clinical characteristics of the





















































































































































































































































































































































































































































































































































































New onset psychotic episodes after VNS implantation have
been reported in the literature [10]. These are may be seen in
patients with DRE when they suddenly become seizure-free, pre-
sumably due to forced normalization. In contrast, one study has
shown an antipsychotic effect after VNS implantation [12].
Recently, Lee et al. [14] reported the first case of forced normaliza-
tion after turning off VNS in a patient suffering from Lennox-
Gastaut syndrome.
Regarding the VNS mechanisms of action, it is thought that
afferent vagal fibers modulate the release of different neurotrans-
mitters in the brainstem involving the locus coeruleus, the nucleus
of the solitary tract, thalamus, and limbic system structures. The
dysregulation of neurotransmitters has also been identified rela-
tive to altered seizure threshold and in psychiatric disorders [15].
In our study, the results showed that patients suffering from
PPE had their ictal or postictal psychotic episodes controlled after
VNS implantation. However, the positive psychotropic effect was
not immediate. Combined time-frame analysis showed a latency
effect of VNS to control psychosis of 8.3 months (range: 6–
36 months). This occurred despite the absemce of seizure control,
however, in three of the cases semiology changed after VNS
implantation.
18F-FDG-PET images showed a normalization of metabolism in
both medial prefrontal cortical areas and anterior insulas in one
of our patients, after VNS implantation. Interestingly, perfusion
changes in the same areas have been described apart from the
epileptogenic foci in psychotic and epileptic patients [16–18]. Nor-
malization of medial frontal metabolism, one of the cortical areas
of the cortico-striatal-thalamic-cortical loop circuits has been sug-
gested as important in schizophrenia patients and has also been
observed in DRE patients suffering psychosis [19].
Although it is speculative, this positive psychotropic effect in
DRE patients suffering ictal and postictal psychosis could be
related to a long-term neuromodulator effect of the VNS, indepen-
dent of its antiseizure effect [20–22]. Despite these encouraging
preliminary results, future research is needed to confirm our find-
ings and to determine whether VNS-induced brain changes are
associated with a favorable outcome in patients with VNS and ictal
or postictal psychosis. Larger prospective studies are recommend-

























































































































The study was approved by the Ethics Committee of the Univer-
sity Hospital of Bellvitge (Hospitalet de Llobregat, Barcelona, Spain)
and conducted in accordance with the Declaration of Helsinki, PR
349/18. The patients’ confidential information was protected5
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patients signed an informed consent.
Acknowledgments
We gratefully thank all the patients who selflessly participated
in the study.
Declaration of Competing Interest
T. Vancamp is also an employee of LivaNova. All other authors
report no conflicts of interest.
Study funding
No financial or any other support has been provided to the
authors to perform this study, nor to compose this manuscript.
Authors’ contributions:
I. Conception and design: M. Falip, T. Vancamp, and M.
Alemany.
II. Administrative support: M. Santurino.
III. Provision of study materials for patients: G. Plans, E. Real, N.
Custal, and J. Mora.
IV. Collection and assembly of data: M. Falip, L. Rodríguez-Bel,
and M. Alemany.
V. Data analysis and interpretation: M. Falip, J. Sala-Padró, and
M. Alemany.
VI. Manuscript writing: All authors.
VII. Final approval of manuscript: All authors
References
[1] Clancy MJ, Clarke MC, Connor DJ, Cannon M, Cotter DR. The prevalence of
psychosis in epilepsy; a systematic review and meta-analysis. BMC Psychiatry
2014;14:75.
[2] Kanner AM, Soto A, Gross-Kanner H. Prevalence and clinical characteristics of
postictal psychiatric symptoms in partial epilepsy. Neurology 2004;62
(5):708–13.
[3] Logsdail SJ, Toone BK. Post-ictal psychoses. A clinical and phenomenological
description. Br J Psychiatry 1988;152:246–52.
[4] Ramos-Perdigués S, Baillés E, Mané A, Carreño M, Donaire A, Rumià J, et al.
Psychiatric symptoms in refractory epilepsy during the first year after surgery.
Neurotherapeutics 2018;15(4):1082–92.6
[5] Jalihal V, Shankar R, Henley W, Parrett M, Tittensor P, McLean BN, et al.
Eslicarbazepine acetate as a replacement for levetiracetam in people with
epilepsy developing behavioral adverse events. Epilepsy Behav
2018;80:365–9.
[6] Wolf P. Acute behavioral symptomatology at disappearance of epileptiform
EEG abnormality. Paradoxical or forced normalization. Adv Neurol
1991;55:127–1427.
[7] Krishnamoorthy ES, Trimble MR, Sander JWAS, Kanner AM. Forced
normalization at the interface between epilepsy and psychiatry. Epilepsy
Behav 2002;3(4):303–8.
[8] Trimble MR. Behaviour changes following temporal lobectomy, with special
reference to psychosis. J Neurol Neurosurg Psychiatry 1992;55(2):89–91.
[9] Buranee K, Teeradej S, Chusak L, Michael M. Epilepsy-related psychoses and
psychotic symptoms are significantly reduced by resective epilepsy surgery
and are not associated with surgery outcome or epilepsy characteristics: a
cohort study. Psychiatry Res 2016;245:333–9.
[10] Blumer D, Davies K, Alexander A, Morgan S. Major psychiatric disorders
subsequent to treating epilepsy by vagus nerve stimulation. Epilepsy Behav
2001;2(5):466–72.
[11] De Herdt V, Boon P, Vonck K, Goossens L, Nieuwenhuis L, Paemeleire K, et al.
Are psychotic symptoms related to vagus nerve stimulation in epilepsy
patients?. Acta Neurol Belg 2003;103(3):170–5.
[12] Koutroumanidis M, Binnie CD, Hennessy MJ, Alarcon, G, Elwes RD, Toone BK,
et al. VNS in patients with previous unsuccessful resective epilepsy surgery:
antiepileptic and psychotropic effects. Acta Neurol Scand. 2003;107(2):117-
121.
[13] Perez SM, Carreno FR, Frazer A, Lodge DJ. Vagal nerve stimulation reverses
aberrant dopamine system function in the methylazoxymethanol acetate
rodent model of schizophrenia. J Neurosci 2014;34(28):9261–7.
[14] Lee S, Denton A, Ladino LD, Waterhouse K, Vitali A, Tellez-Zenteno JF. Forced
normalization after turning off vagus nerve stimulation in Lennox-Gastaut
syndrome. Epilepsy Behav Case Rep 2019;11:81–3.
[15] Vonck K, Boon P. The mechanism of action of vagus nerve stimulation therapy.
Eur Neurol Rev 2008;3(2):97–100.
[16] Allebone J, Kanaan R, Wilson SJ. Systematic review of structural and functional
brain alterations in psychosis of epilepsy. J Neurol Neurosurg Psychiatry
2018;89:611–7.
[17] Fong GCY, Fong KY, Mak W, Tsang KL, Chan KH, Cheung RT, et al. Postictal
psychosis related regional cerebral hyperperfusion. Cit J Neurol Neurosurg
Psychiatry 2000;68:100–1.
[18] Hasan A, Wolff-Menzler C, Pfeiffer S, Falkai P, Weidinger E, Jobst A, et al.
Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment
of schizophrenia: a bicentric randomized controlled pilot study. Eur Arch
Psychiatry Clin Neurosci 2015;265(7):589–600.
[19] Peters SK, Dunlop K, Downar J. Cortico-striatal-thalamic loop circuits of the
salience network: a central pathway in psychiatric disease and treatment.
Front Syst Neurosci 2016;10:104.
[20] Graat I, Figee M, Denys D. The application of deep brain stimulation in the
treatment of psychiatric disorders. Int Rev Psychiatry 2017;29(2):178–90.
[21] Hadar R, Bikovski L, Soto-Montenegro ML, Schimke J, Maier P, Ewing S, et al.
Early neuromodulation prevents the development of brain and behavioral
abnormalities in a rodent model of schizophrenia. Mol Psychiatry 2018;23
(4):943–51.
[22] Corripio I, Roldán A, Sarró S, McKenna PJ, Alonso-Solís A, Rabella M, et al. Deep
brain stimulation in treatment resistant schizophrenia: a pilot randomized
cross-over clinical trial. EBioMedicine 2020;51:102568.
